AI assistant
RIGEL PHARMACEUTICALS INC — Director's Dealing 2018
Jul 6, 2018
32801_dirs_2018-07-05_9d0060b6-0a4d-44e0-9414-7e04523aa512.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RIGEL PHARMACEUTICALS INC (RIGL)
CIK: 0001034842
Period of Report: 2018-07-02
Reporting Person: Duliege Anne-Marie (EVP & Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-07-02 | Common Stock | S | 5000 | $2.7864 | Disposed | 0 | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 26,2018.
F2: The Reporting Person purchased these shares on June 29, 2018 under the Issuer's Employee Stock Purchase Plan.
F3: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions ranging from $2.76 to $2.80. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each such separate price.